RNA•prnewswire•
Avidity Biosciences Announces Expected Record Date for Spin-Off
Summary
SAN DIEGO, Feb. 2, 2026 /PRNewswire/ -- Avidity Biosciences, Inc. ("Avidity") (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates ("AOCs™") to profoundly improve people's lives, today announced that...
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on February 3, 2026 by prnewswire